stockrowPulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
Follow PLSE
Alert me
Pulse Biosciences, Inc (PLSE) EPS (diluted)
Pulse Biosciences, Inc's EPS (diluted) for fiscal 2025 was −$1.08, compared with −$0.92 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.21. Over the past ten years it has ranged from −$2.28 (fiscal 2021) to −$0.37 (fiscal 2015); the current reading is higher than 64% of that period. Pulse Biosciences, Inc ranks 37th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.08 | — |
| FY2024 | −$0.92 | — |
| FY2023 | −$0.88 | — |
| FY2022 | −$1.72 | — |
| FY2021 | −$2.28 | — |
| FY2020 | −$2.14 | — |
| FY2019 | −$2.26 | — |
| FY2018 | −$2.20 | — |
| FY2017 | −$1.73 | — |
| FY2016 | −$0.86 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.32 | — |
| Jun 2026 | −$0.36 | — |
| Mar 2026 | −$0.27 | — |
| Dec 2025 | −$0.26 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| NVST Envista Holdings Corporation compare | $3.92 |
| MMSI Merit Medical Systems, Inc. compare | $2.66 |
| ICUI ICU Medical, Inc. compare | $2.39 |
| STVN Stevanato Group S.p.A. compare | $0.59 |
| ATRC AtriCure, Inc. compare | $0.30 |
| WRBY Warby Parker Inc. compare | $0.06 |
| MMED MiniMed Group, Inc. compare | −$0.59 |
| PLSE Pulse Biosciences, Inc | −$1.21 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PLSE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement